Skip to main content
All lobbying filings

ADVANCED POLICY CONSULTING, LLC

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) · Trade association for the Pharmaceutical Research and Manufacturer's of America

 Filing 1st Quarter - Report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 14, 2026
Income
$40,000.00
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 3
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 3
  • HR 2214
    DRUG Act
  • HR 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • S 832
    EPIC Act of 2025
 Lobbying activity 1
Health Issues

Monitoring healthcare legislation. Education regarding market based solutions to bring down the cost of drug prices. Education regarding the dangers of global counterfeit medications. Education regard the International Pricing Index (IPI) Model, which would import single-payer government run price controls that limit innovation and patient access to life saving therapies. Support for PBM reform. HR 2214 -- "DRUG Act" HR 1492 -- "To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program." S.832 - "EPIC Act of 2025." Education regarding the Most Favored Nation Executive Order.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem